Literature DB >> 21217359

Comparison of the efficacy of fibrates on hypertriglyceridemic phenotypes with different genetic and clinical characteristics.

Diane Brisson1, Julie Méthot, Karine Tremblay, Monique Tremblay, Patrice Perron, Daniel Gaudet.   

Abstract

UNLABELLED: Hypertriglyceridemia is a frequent and heterogeneous clinical trait, which modulates the risk of disease. Fibrates constitute an effective class of triglyceride-lowering agents.
OBJECTIVE: To evaluate the effect of fibrates on fasting plasma triglycerides and other lipids levels in hypertriglyceridemia phenotypes with different genetic and clinical characteristics.
METHODS: This study included 146 fasting adults: 15 with lactescent plasma and severe hypertriglyceridemia (triglyceride ≥ 10 mmol/l) and 131 with clear plasma and moderate hypertriglyceridemia (2 ≤ triglycerides <10 mmol/l). Expost comparisons of the effect of fibrates on fasting triglycerides and other lipids were made using Student's paired two-tailed t-test.
RESULTS: Response to these fibrates differed significantly across the studied hypertriglyceridemia subtypes: patients with severe hypertriglyceridemia because of lipoprotein lipase deficiency and those with moderate hypertriglyceridemia because of glycerol kinase deficiency did not respond at all, whereas patients with palmar xanthomas and severe or moderate hypertriglyceridemia because of apolipoprotein (apo) E resistance (type-III dysbetalipoproteinemia, most often associated with the apo E2 allele) responded significantly better (P<0.001) than all other subtypes on several lipid fractions.
CONCLUSION: These results indicate that genetic factors known to contribute to the etiology and clinical expression of hypertriglyceridemia subtypes also modulate the response to triglyceride-lowering drugs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21217359     DOI: 10.1097/FPC.0b013e328340095e

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  6 in total

Review 1.  Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence.

Authors:  Hong Sheng Cheng; Wei Ren Tan; Zun Siong Low; Charlie Marvalim; Justin Yin Hao Lee; Nguan Soon Tan
Journal:  Int J Mol Sci       Date:  2019-10-11       Impact factor: 5.923

2.  Rare PPARA variants and extreme response to fenofibrate in the Genetics of Lipid-Lowering Drugs and Diet Network Study.

Authors:  Marguerite R Irvin; Qunyuan Zhang; Edmond K Kabagambe; Rodney T Perry; Robert J Straka; Hemant K Tiwari; Ingrid B Borecki; Lawrence C Shimmin; Colin Stuart; Yu Zhong; James E Hixson; Donna K Arnett
Journal:  Pharmacogenet Genomics       Date:  2012-05       Impact factor: 2.089

3.  Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome.

Authors:  Charles Daniel Meyers; Karine Tremblay; Ahmed Amer; Jin Chen; Liewen Jiang; Daniel Gaudet
Journal:  Lipids Health Dis       Date:  2015-02-18       Impact factor: 3.876

4.  Association of CTRC and SPINK1 gene variants with recurrent hospitalizations for pancreatitis or acute abdominal pain in lipoprotein lipase deficiency.

Authors:  Karine Tremblay; Camélia Dubois-Bouchard; Diane Brisson; Daniel Gaudet
Journal:  Front Genet       Date:  2014-04-22       Impact factor: 4.599

5.  Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial.

Authors:  D Gaudet; J Méthot; S Déry; D Brisson; C Essiembre; G Tremblay; K Tremblay; J de Wal; J Twisk; N van den Bulk; V Sier-Ferreira; S van Deventer
Journal:  Gene Ther       Date:  2012-06-21       Impact factor: 5.250

6.  Marked effects of novel selective peroxisome proliferator-activated receptor α modulator, pemafibrate in severe hypertriglyceridemia: preliminary report.

Authors:  Chie Iitake; Daisaku Masuda; Masahiro Koseki; Shizuya Yamashita
Journal:  Cardiovasc Diabetol       Date:  2020-11-27       Impact factor: 9.951

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.